TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.00 (+2.24%)
Close on Nov 20, 2026Market cap $9.89MP/E –Yield –
TScan Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
TScan Therapeutics's shares outstanding was 130M at Jun 30, 2026. For fiscal 2025 it was 130M, up 15.9% from the year before. The highest annual figure on record is 130M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 130M | +15.9% |
| FY2024 | Dec 31, 2024 | 112M | +70.7% |
| FY2023 | Dec 31, 2023 | 66M | +172.8% |
| FY2022 | Dec 31, 2022 | 24M | +106.2% |
| FY2021 | Dec 31, 2021 | 12M | +1173.2% |
| FY2020 | Dec 31, 2020 | 1M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 130M | +0.2% |
| Q1 FY2026 | Mar 31, 2026 | 130M | +0.2% |
| Q4 FY2025 | Dec 31, 2025 | 130M | +7.5% |
| Q3 FY2025 | Sep 30, 2025 | 130M | +9.4% |
| Q2 FY2025 | Jun 30, 2025 | 130M | +14.4% |
| Q1 FY2025 | Mar 31, 2025 | 130M | +36.7% |
| Q4 FY2024 | Dec 31, 2024 | 121M | +26.9% |
| Q3 FY2024 | Sep 30, 2024 | 119M | +25.2% |
| Q2 FY2024 | Jun 30, 2024 | 113M | +140.3% |
| Q1 FY2024 | Mar 31, 2024 | 95M | +291.6% |
| Q4 FY2023 | Dec 31, 2023 | 95M | +295.6% |
| Q3 FY2023 | Sep 30, 2023 | 95M | +293.9% |
| Q2 FY2023 | Jun 30, 2023 | 47M | +96.2% |
| Q1 FY2023 | Mar 31, 2023 | 24M | +1.0% |
| Q4 FY2022 | Dec 31, 2022 | 24M | +21.1% |
| Q3 FY2022 | Sep 30, 2022 | 24M | +1634.5% |
| Q2 FY2022 | Jun 30, 2022 | 24M | +1874.2% |
| Q1 FY2022 | Mar 31, 2022 | 24M | +2357.0% |
| Q3 FY2021 | Sep 30, 2021 | 20M | +1883.9% |
| Q2 FY2021 | Jun 30, 2021 | 1M | +52.8% |
| Q1 FY2021 | Mar 31, 2021 | 1M | – |
| Q4 FY2020 | Dec 31, 2020 | 1M | – |
| Q3 FY2020 | Sep 30, 2020 | 1M | – |
| Q2 FY2020 | Jun 30, 2020 | 1M | – |
See a number that looks wrong?